ArticleAmerican journal of cardiovascular disease2025
Trends and demographic disparities in heart failure mortality rates in non-alcoholic fatty liver disease: a population-based retrospective study in the United States from 1999 to 2020.
Article in American journal of cardiovascular disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- HFpEF and MASLD: converging mechanisms and clinical implications.Nature reviews. Cardiology · 2026Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives.Reviews in cardiovascular medicine · 2026Review
- Trends in atrial fibrillation and non-alcoholic fatty liver disease-related mortality in the United States from 1999 to 2020: a CDC WONDER analysis.Annals of medicine and surgery (2012) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to analyze two decades heart failure (HF) mortality data in Non-Alcoholic Fatty Liver Disease (NAFLD), now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), in the United States (US), identifying patterns and disparities in mortality rates.
methodsA retrospective analysis was conducted using mortality data from the CDC WONDER database spanning 1999-2020. Age-adjusted mortality rates (AAMRs) per 1,000,000 persons were calculated, and trends were assessed using Average Annual Percentage Change (AAPC) and Annual Percent Change (APC) using Joinpoint 5.0.2. Data were stratified by year, sex, race/ethnicity, urbanization, and census regions.
resultsFrom 1999-2020, 68,436 HF-related deaths occurred among US adults with NAFLD. The overall AAMR increased from 12.49 in 1999 to 24.30 in 2020, with an AAPC of 3.05 (95% CI: 2.80 to 3.31, P < 0.001), with a steep rise in AAMR from 2017-2020 and an APC of 12.35 (95% CI: 9.71 to 15.99). American Indian or Alaskan natives had the highest AAMRs (28.63), followed by Hispanics (20.05), and African Americans or Blacks (14.51). The highest mortality regionally was in the Southern region (AAMR: 16.05) and nonmetropolitan areas had higher AAMRs than metropolitan areas (16.63 vs. 13.76).
conclusionsThis analysis demonstrated increasing mortality rates from HF in NAFLD, with a sharper increase in recent years. This also showed nonmetropolitan areas, the Southern region of the US, and minority populations had higher mortality rates, which highlights at-risk populations and opportunities for important public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.